CEL-SCI Corp CEO Geert Kersten joined Steve Darling from Proactive to share news the company has detailed, in a letter to shareholders, the good results from its Phase 3 study of our investigational cancer immunotherapy, Multikine. Kersten telling Proactive, the key takeaways include 16% of Multikine patients in the radiation-only group in the study had at least a 30% tumor reduction within just a few weeks of treatment before surgery. Five of these responders had their tumors completely disappear before surgery.
CEL-SCI Corp letter to shareholders details positive results from Phase 3 study of Multikine
